BackNewAmsterdam Pharma Company NV - Warrants (15/11/2027) Overview

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Total Current Liabilities

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s total current liabilities is $67M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$67.42M
64.79% YoYΔ $26.51M vs prior year quarter

Peer average

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Total Current Liabilities History

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) vs. peers: Total Current Liabilities Comparison

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) (NAMSW) FAQ

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s total current liabilities stands at $67M as of March 2026. That compares with $41M in the prior-year period — up 64.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) reported $67M in total current liabilities versus $41M a year earlier — a 64.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $41M in the prior-year period — up 64.8% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s total current liabilities evolved across reporting periods, while the comparison chart places NAMSW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.